Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Orforglipron

Foundayo

Stage ApprovedStale

Sponsor Eli Lilly and Company

Route tablet

Class Oral small molecule

Mechanism small-molecule nonpeptide oral GLP-1 receptor agonist

Sources

fda, as of 2026-04-01Stale

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220934Orig1s000ltr.pdf

Eli Lilly and Company. This NDA provides for the use of Foundayo (orforglipron) tablets in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. It is approved, effective on the date of this letter.

NDA 220934 approval letter, signature date 04/01/2026

registry, as of 2026-08-14Stale

https://clinicaltrials.gov/study/NCT05869903

Protocol section, NCT05869903 ATTAIN-1, last update posted 2026-08-14

registry, as of 2026-04-17Stale

https://clinicaltrials.gov/study/NCT05803421

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 2749. Conditions Type 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidney Disease. The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits

ClinicalTrials.gov NCT05803421 protocol and results modules

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07794579

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 2001. Conditions Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal. This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.

ClinicalTrials.gov NCT07794579 protocol and results modules

registry, as of 2026-09-04Stale

https://clinicaltrials.gov/study/NCT05872620

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1613. Conditions Obesity; Overweight; Type 2 Diabetes. This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits. Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline Placebo 24.4 Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline 6 mg Orforglipron QD 49.8 Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline 12 mg Orfor

ClinicalTrials.gov NCT05872620 protocol and results modules

registry, as of 2026-07-31Stale

https://clinicaltrials.gov/study/NCT06993792

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1400. Conditions Obesity; Overweight; Type 2 Diabetes. The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they wi

ClinicalTrials.gov NCT06993792 protocol and results modules

registry, as of 2026-11-04

https://clinicaltrials.gov/study/NCT07202884

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1000. Conditions Urinary Incontinence,Stress. The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during m

ClinicalTrials.gov NCT07202884 protocol and results modules

registry, as of 2026-05-29Stale

https://clinicaltrials.gov/study/NCT06948422

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening). Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 974. Conditions Hypertension. The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overwei

ClinicalTrials.gov NCT06948422 protocol and results modules

registry, as of 2026-10-08Stale

https://clinicaltrials.gov/study/NCT07153471

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 800. Conditions Osteoarthritis. The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last abo

ClinicalTrials.gov NCT07153471 protocol and results modules

registry, as of 2026-07-29Stale

https://clinicaltrials.gov/study/NCT06972459

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 800. Conditions Obesity; Overweight. The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study

ClinicalTrials.gov NCT06972459 protocol and results modules

registry, as of 2026-09-14Stale

https://clinicaltrials.gov/study/NCT06649045

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 712. Conditions OSA; Overweight or Obesity. Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have modera

ClinicalTrials.gov NCT06649045 protocol and results modules

registry, as of 2026-04-20Stale

https://clinicaltrials.gov/study/NCT06972472

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 600. Conditions Obesity; Overweight; Type 2 Diabetes. The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the s

ClinicalTrials.gov NCT06972472 protocol and results modules

registry, as of 2026-05-29Stale

https://clinicaltrials.gov/study/NCT06952530

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 487. Conditions Hypertension. GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

ClinicalTrials.gov NCT06952530 protocol and results modules

registry, as of 2026-05-29Stale

https://clinicaltrials.gov/study/NCT06948435

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 487. Conditions Hypertension; Overweight or Obesity. GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

ClinicalTrials.gov NCT06948435 protocol and results modules

registry, as of 2026-06-04Stale

https://clinicaltrials.gov/study/NCT06584916

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN). Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 376. Conditions Obesity; Overweight. The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable semaglutide (Wegovy) in the SURMOUNT-5 trial (NCT0

ClinicalTrials.gov NCT06584916 protocol and results modules

registry, as of 2026-07-20Stale

https://clinicaltrials.gov/study/NCT05931380

A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 238. Conditions Obesity. The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems. Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline Placebo QD 15.0 Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline 6 mg Orforglipron QD 45.9 Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline 12 mg Orforglipron QD 61.4 Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From B

ClinicalTrials.gov NCT05931380 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07790861

A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 192. Conditions Obesity; Overweight. The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).

ClinicalTrials.gov NCT07790861 protocol and results modules

registry, as of 2026-11-04

https://clinicaltrials.gov/study/NCT06672939

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 150. Conditions Obesity; Overweight. The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. P

ClinicalTrials.gov NCT06672939 protocol and results modules

registry, as of 2026-11-04

https://clinicaltrials.gov/study/NCT06672549

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040). Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 125. Conditions Obesity; Overweight. The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

ClinicalTrials.gov NCT06672549 protocol and results modules

registry, as of 2026-07-27Stale

https://clinicaltrials.gov/study/NCT07729332

Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation. Overall status NOT_YET_RECRUITING. Phases PHASE4. Lead sponsor Massachusetts General Hospital. Enrollment 60. Conditions Obesity. This study will compare the effect of orforglipron and phentermine on weight maintenance.

ClinicalTrials.gov NCT07729332 protocol and results modules

registry, as of 2026-07-17Stale

https://clinicaltrials.gov/study/NCT06440980

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 533. Conditions Healthy; Obese; Overweight; Obesity. The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effe

ClinicalTrials.gov NCT06440980 protocol and results modules

registry, as of 2026-02-25Stale

https://clinicaltrials.gov/study/NCT06824051

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 120. Conditions Obesity; Overweight. The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.

ClinicalTrials.gov NCT06824051 protocol and results modules

registry, as of 2026-09-11Stale

https://clinicaltrials.gov/study/NCT07793019

IBI3042 Study in Healthy Participants and Overweight or Obese Participants. Overall status RECRUITING. Phases PHASE1. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 104. Conditions Overweight; Healthy Participants; Obesity. This is a Phase 1 study of IBI3042, an investigational oral medicine being developed as a potential treatment for overweight and obesity. The study has two parts. Part A will evaluate single doses of IBI3042 in healthy adults. Part B will evaluate repeated doses for 13 weeks in a

ClinicalTrials.gov NCT07793019 protocol and results modules

registry, as of 2026-05-22Stale

https://clinicaltrials.gov/study/NCT06186622

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants. Overall status COMPLETED. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 50. Conditions Healthy; Obese; Overweight. The main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that enters the bloodstream and how long it takes the body

ClinicalTrials.gov NCT06186622 protocol and results modules

publication, as of 2025-11-05Stale

https://pubmed.ncbi.nlm.nih.gov/40960239/

Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of

PMID 40960239

Studies

ATTAIN-1

Registry NCT05869903

Phase Phase 3

Status Active, not recruiting

Enrollment 3127

Start 2023-06-05

Primary completion 2025-07-25

Placebo

6 mg Orforglipron

Dose 6 mg

12 mg Orforglipron

Dose 12 mg

36 mg Orforglipron

Dose 36 mg

ACHIEVE-4

Registry NCT05803421

Phase Phase 3

Status Completed

Enrollment 2749

Start 2023-04-03

Primary completion 2026-03-16

Study completion 2026-03-16

Catalyst Primary completion. 2026-03-16. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Orforglipron

Regimen once daily

Population Type 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidney Disease

Insulin Glargine

Regimen once daily

Population Type 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidney Disease

ATTAIN-NOW

Registry NCT07794579

Phase Phase 3

Status Recruiting

Enrollment 2001

Start 2026-08-26

Orforglipron

Regimen once daily

Comparator placebo

Population Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal

Orforglipron to Placebo

Regimen once daily

Population Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal

Placebo to Orforglipron

Regimen once daily

Population Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal

ATTAIN-2

Registry NCT05872620

Phase Phase 3

Status Completed

Enrollment 1613

Start 2023-06-05

Primary completion 2025-08-08

Study completion 2025-08-08

Catalyst Primary completion. 2025-08-08. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Placebo

Regimen every 4 weeks

Weeks 72

Population Obesity; Overweight; Type 2 Diabetes

participants with at least 5 percent body weight loss, 24.4 %, week 72Stale

participants with at least 10 percent body weight loss, 7 %, week 72Stale

participants with at least 15 percent body weight loss, 1.9 %, week 72Stale

deaths

participants with diarrhoea, 94 participantsStale

participants with nausea, 53 participantsStale

participants with vomiting, 24 participantsStale

6 mg Orforglipron QD

Dose 6 mg

Regimen every 4 weeks

Weeks 72

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

participants with at least 5 percent body weight loss, 49.8 %, week 72Stale

participants with at least 10 percent body weight loss, 23.9 %, week 72Stale

participants with at least 15 percent body weight loss, 7.3 %, week 72Stale

deaths

participants with diarrhoea, 70 participantsStale

participants with nausea, 66 participantsStale

participants with vomiting, 42 participantsStale

12 mg Orforglipron QD

Dose 12 mg

Regimen every 4 weeks

Weeks 72

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

participants with at least 5 percent body weight loss, 60.2 %, week 72Stale

participants with at least 10 percent body weight loss, 35.5 %, week 72Stale

participants with at least 15 percent body weight loss, 17.7 %, week 72Stale

deaths

participants with diarrhoea, 82 participantsStale

participants with nausea, 103 participantsStale

participants with vomiting, 67 participantsStale

36 mg Orforglipron QD

Dose 36 mg

Regimen every 4 weeks

Weeks 72

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Registry NCT06993792

Phase Phase 3

Status Active, not recruiting

Enrollment 1400

Start 2025-05-15

Orforglipron Dose 1 (Study GZP1)

Regimen once daily

Weeks 4

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

Orforglipron Dose 2 (Study GZP1)

Regimen once daily

Weeks 4

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

Orforglipron Dose 3 (Study GZP1)

Regimen once daily

Weeks 4

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

Orforglipron Dose 4 (Study GZP1)

Regimen once daily

Weeks 4

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

Placebo (Study GZP1)

Regimen once daily

Weeks 4

Population Obesity; Overweight; Type 2 Diabetes

Orforglipron Dose 1 (Study GZP2)

Regimen once daily

Weeks 4

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

Orforglipron Dose 2 (Study GZP2)

Regimen once daily

Weeks 4

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

Orforglipron Dose 3 (Study GZP2)

Regimen once daily

Weeks 4

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

Orforglipron Dose 4 (Study GZP2)

Regimen once daily

Weeks 4

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

Placebo (Study GZP2)

Regimen once daily

Weeks 4

Population Obesity; Overweight; Type 2 Diabetes

RESTRAIN-SUI

Registry NCT07202884

Phase Phase 3

Status Recruiting

Enrollment 1000

Start 2025-09-30

Orforglipron (GZS1)

Regimen once daily

Weeks 58

Comparator placebo

Population Urinary Incontinence,Stress

Placebo (GZS1)

Regimen once daily

Weeks 58

Population Urinary Incontinence,Stress

Orforglipron (GZS2)

Regimen once daily

Weeks 58

Comparator placebo

Population Urinary Incontinence,Stress

Placebo (GZS2)

Regimen once daily

Weeks 58

Population Urinary Incontinence,Stress

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

Registry NCT06948422

Phase Phase 3

Status Active, not recruiting

Enrollment 974

Start 2025-04-30

Orforglipron (GZL1)

Regimen once daily

Population Hypertension

Orforglipron (GZL2)

Regimen once daily

Population Hypertension

ATTAIN-OA PAIN

Registry NCT07153471

Phase Phase 3

Status Active, not recruiting

Enrollment 800

Start 2025-09-15

Orforglipron (GZT1)

Regimen once daily

Weeks 74

Comparator placebo

Population Osteoarthritis

Placebo (GZT1)

Regimen once daily

Weeks 74

Population Osteoarthritis

Orforglipron (GZT2)

Regimen once daily

Weeks 74

Comparator placebo

Population Osteoarthritis

Placebo (GZT2)

Regimen once daily

Weeks 74

Population Osteoarthritis

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Registry NCT06972459

Phase Phase 3

Status Active, not recruiting

Enrollment 800

Start 2025-05-15

Orforglipron Dose 1

Regimen once daily

Comparator placebo

Population Obesity; Overweight

Orforglipron Dose 2

Regimen once daily

Comparator placebo

Population Obesity; Overweight

Orforglipron Dose 3

Regimen once daily

Comparator placebo

Population Obesity; Overweight

Orforglipron Dose 4

Regimen once daily

Comparator placebo

Population Obesity; Overweight

Placebo

Regimen once daily

Population Obesity; Overweight

ATTAIN-OSA

Registry NCT06649045

Phase Phase 3

Status Completed

Enrollment 712

Start 2024-10-22

Primary completion 2026-07-21

Study completion 2026-07-30

Catalyst Primary completion. 2026-07-21. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Orforglipron

Regimen once daily

Comparator placebo

Population OSA; Overweight or Obesity

Placebo

Regimen once daily

Population OSA; Overweight or Obesity

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Registry NCT06972472

Phase Phase 3

Status Active, not recruiting

Enrollment 600

Start 2025-05-19

Orforglipron Dose 1

Regimen once daily

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

Orforglipron Dose 2

Regimen once daily

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

Orforglipron Dose 3

Regimen once daily

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

Orforglipron Dose 4

Regimen once daily

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes

Placebo

Regimen once daily

Population Obesity; Overweight; Type 2 Diabetes

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

Registry NCT06952530

Phase Phase 3

Status Active, not recruiting

Enrollment 487

Start 2025-04-30

Orforglipron

Regimen once daily

Comparator placebo

Population Hypertension

Placebo

Regimen once daily

Population Hypertension

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Registry NCT06948435

Phase Phase 3

Status Active, not recruiting

Enrollment 487

Start 2025-04-30

Orforglipron

Regimen once daily

Comparator placebo

Population Hypertension; Overweight or Obesity

Placebo

Regimen once daily

Population Hypertension; Overweight or Obesity

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

Registry NCT06584916

Phase Phase 3

Status Completed

Enrollment 376

Start 2024-09-13

Primary completion 2025-11-21

Study completion 2025-11-21

Catalyst Primary completion. 2025-11-21. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Orforglipron

Regimen once daily

Comparator placebo

Population Obesity; Overweight

Placebo

Regimen once daily

Population Obesity; Overweight

ATTAIN-J

Registry NCT05931380

Phase Phase 3

Status Completed

Enrollment 238

Start 2023-07-31

Primary completion 2025-06-19

Study completion 2025-06-19

Catalyst Primary completion. 2025-06-19. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Placebo QD

Regimen every 4 weeks

Weeks 72

Population Obesity

participants with at least 5 percent body weight loss, 15 %, week 72Stale

participants with at least 10 percent body weight loss, 3.33 %, week 72Stale

participants with at least 15 percent body weight loss, 0 %, week 72Stale

participants with at least 20 percent body weight loss, 0 %, week 72Stale

deaths

participants with diarrhoea, 2 participantsStale

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

6 mg Orforglipron QD

Dose 6 mg

Regimen every 4 weeks

Weeks 72

Comparator placebo

Population Obesity

participants with at least 5 percent body weight loss, 45.9 %, week 72Stale

participants with at least 10 percent body weight loss, 18.03 %, week 72Stale

participants with at least 15 percent body weight loss, 9.84 %, week 72Stale

participants with at least 20 percent body weight loss, 3.28 %, week 72Stale

deaths

participants with diarrhoea, 9 participantsStale

participants with nausea, 8 participantsStale

participants with vomiting, 4 participantsStale

12 mg Orforglipron QD

Dose 12 mg

Regimen every 4 weeks

Weeks 72

Comparator placebo

Population Obesity

participants with at least 5 percent body weight loss, 61.4 %, week 72Stale

participants with at least 10 percent body weight loss, 35.09 %, week 72Stale

participants with at least 15 percent body weight loss, 22.81 %, week 72Stale

participants with at least 20 percent body weight loss, 12.28 %, week 72Stale

deaths

participants with diarrhoea, 4 participantsStale

participants with nausea, 9 participantsStale

participants with vomiting, 5 participantsStale

36 mg Orforglipron QD

Dose 36 mg

Regimen every 4 weeks

Weeks 72

Comparator placebo

Population Obesity

ATTAIN-CN

Registry NCT07790861

Phase Phase 3

Status Not yet recruiting

Enrollment 192

Orforglipron

Regimen daily

Weeks 53

Comparator placebo

Population Obesity; Overweight

Placebo

Regimen daily

Weeks 53

Population Obesity; Overweight

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Registry NCT06672939

Phase Phase 3

Status Recruiting

Enrollment 150

Start 2024-11-18

Orforglipron

Regimen once daily

Weeks 156

Comparator placebo

Population Obesity; Overweight

Placebo

Regimen once daily

Weeks 156

Population Obesity; Overweight

ADVANCE

Registry NCT06672549

Phase Phase 3

Status Recruiting

Enrollment 125

Start 2024-11-18

Orforglipron (ISA PW01)

Population Obesity; Overweight

Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation

Registry NCT07729332

Phase Phase 4

Status Not yet recruiting

Enrollment 60

Start 2026-11-01

Primary completion 2031-07-31

Study completion 2031-07-31

Phentermine

Population Obesity

Orforglipron

Population Obesity

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

Registry NCT06440980

Phase Phase 1

Status Completed

Enrollment 533

Start 2024-06-24

Primary completion 2025-06-02

Study completion 2025-06-02

Catalyst Primary completion. 2025-06-02. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3)

Regimen once daily

Weeks 22

Population Healthy; Obese; Overweight; Obesity

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

Registry NCT06824051

Phase Phase 1

Status Completed

Enrollment 120

Start 2025-02-17

Primary completion 2026-01-26

Study completion 2026-01-26

Catalyst Primary completion. 2026-01-26. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Orforglipron

Comparator placebo

Population Obesity; Overweight

Placebo

Population Obesity; Overweight

IBI3042 Study in Healthy Participants and Overweight or Obese Participants

Registry NCT07793019

Phase Phase 1

Status Recruiting

Enrollment 104

Start 2026-09-07

Primary completion 2027-09-06

Study completion 2028-01-26

Catalyst Primary completion. 2027-09-06. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Investigational Drug: IBI3042 (Part A)

Comparator placebo

Population Overweight; Healthy Participants; Obesity

Investigational Drug: IBI3042 (Part B)

Comparator placebo

Population Overweight; Healthy Participants; Obesity

Matching Placebo (Part B)

Population Overweight; Healthy Participants; Obesity

Orforglipron (Part B)

Comparator placebo

Population Overweight; Healthy Participants; Obesity

Matching Placebo (Part A)

Population Overweight; Healthy Participants; Obesity

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

Registry NCT06186622

Phase Phase 1

Status Completed

Enrollment 50

Start 2024-01-02

Primary completion 2024-07-10

Study completion 2024-07-10

Cohort 1: Oral Drug Dosing With or Without Orforglipron Co-Administration

Regimen once daily

Weeks 24

Population Healthy; Obese; Overweight

Cohort 2: Oral Drug Dosing With or Without Orforglipron Co-Administration

Regimen once daily

Weeks 24

Population Healthy; Obese; Overweight